3-[4-(o-tolyl)piperazin-1-yl]propan-1-amine | 20529-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[4-(o-tolyl)piperazin-1-yl]propan-1-amine
• 英文别名: 3-(4-o-tolyl-piperazin-1-yl)-propylamine；3-[4-(2-Methylphenyl)piperazin-1-yl]propan-1-amine
• CAS: 20529-21-9
• 化学式: C₁₄H₂₃N₃
• mdl: MFCD15732525
• 分子量: 233.357
• InChiKey: IKZPKNILUZZSBA-UHFFFAOYSA-N

物化性质

• 沸点：
  129 °C(Press: 0.15 Torr)
• 密度：
  1.028±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,3-bis(4-methoxyphenyl)pentanedioic acid anhydride 、 3-[4-(o-tolyl)piperazin-1-yl]propan-1-amine 在 吡啶 、 乙酸酐 作用下， 以60%的产率得到
  参考文献：
  名称：

  Korgaonkar; Kulkarni; Samant, Journal of the Indian Chemical Society, 1983, vol. 60, # 9, p. 874 - 876

  摘要：

  DOI：
• 作为产物：
  描述：

  3-[4-(2-甲基苯基)哌嗪-1-基]丙腈 在 W-6 Raney nickel 氢气 作用下， 以 甲醇 、 氨 为溶剂， 反应 8.0h， 生成 3-[4-(o-tolyl)piperazin-1-yl]propan-1-amine
  参考文献：
  名称：

  Korgaonkar; Kulkarni; Samant, Journal of the Indian Chemical Society, 1983, vol. 60, # 9, p. 874 - 876

  摘要：

  DOI：

文献信息

• Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors
  作者：Angela G. Koryakova、Yan A. Ivanenkov、Elena A. Ryzhova、Elena A. Bulanova、Ruben N. Karapetian、Olga V. Mikitas、Eugeny A. Katrukha、Vasily I. Kazey、Ilya Okun、Dmitry V. Kravchenko、Yan V. Lavrovsky、Oleg M. Korzinov、Alexandre V. Ivachtchenko

  DOI：10.1016/j.bmcl.2007.11.121

  日期：2008.6

  heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamide inhibitors of GSK-3beta kinase are described. The inhibitory activity of the synthesized compounds is highly dependent on the character of substituents in the phenyl ring and the nature of terminal heterocyclic fragment of the core molecular scaffold. The most potent compounds from this series contain 3,4-di-methyl

  一系列新型的GSK-3beta芳基和杂芳基取代的N- [3-（4-苯基哌嗪-1-基）丙基] -1,2,4-恶二唑-5-羧酰胺抑制剂的合成，生物学评估和SAR依赖性描述了激酶。合成化合物的抑制活性高度依赖于苯环中取代基的特性以及核心分子支架的末端杂环片段的特性。该系列中最有效的化合物在苯环和与1,2,4-恶二唑杂环相连的3-吡啶片段内包含3,4-二甲基或2-甲氧基取代基。这些化合物选择性抑制GSK-3beta激酶，其IC（50）值分别为0.35和0.41 microM。
• [EN] PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)<br/>[FR] PHENYL CARBAMATES ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME HYDROLASE D'AMIDES D'ACIDES GRAS (FAAH) ET MODULATEURS DU RÉCEPTEUR D3 DE LA DOPAMINE (D3DR)
  申请人：FOND ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：WO2015007615A1

  公开（公告）日：2015-01-22

  The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar', R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.

  该发明提供了式（I）的化合物或其药用可接受的盐，其中Ar'，R1，R2，R3，R4，X，Y如发明描述中所定义，作为多靶点定向配体（MTDLs），同时是脂肪酸酰胺水解酶（FAAH）酶的抑制剂和D3多巴胺受体（D3DR）的调节剂，以及它们的制备方法、配方和治疗应用。
• Basic amides of 2,4,5-trichlorophenoxyacetic, 2,4,6-trimethylphenoxyacetic and 4-bromo-3,5-dimethylphenoxyacetic acid and some related compounds; Synthesis and pharmacological screening
  作者：Vladimír Valenta、Jiří Němec、Miroslav Protiva

  DOI：10.1135/cccc19831089

  日期：——

  Reactions of methyl esters II of 2,4,5-trichlorophenoxyacetic (Ia), 2,4,6-trimethylphenoxyacetic (Ib) and 4-bromo-3,5-dimethylphenoxyacetic acid (Ic) with 2-diethylaminoethylamine, 2-morpholinoethylamine, 3-morpholinopropylamine, 1-methylpiperazine, 3-(4-methylpiperazino)propylamine, 3-[4-(2-tolyl)piperazino]propylamine and 1,4-bis(3-aminopropyl)piperazine in boiling ethanol gave the basic amides Va-XIc which were isolated as hydrochlorides. Reactions of the acid chlorides IVa and IVb with 1,4-bis(2-hydroxyethyl)piperazine and 1,4-bis(3-hydroxypropyl)piperazine in dimethylformamide resulted directly in dihydrochlorides of diesters XIIab and XIIIab. The compounds prepared have only weak CNS effects (mostly of the depressant type); they have local anaesthetic, mild hypotensive (some of them adrenolytic), antiarrhythmic and peripheral vasodilating activities.

  甲酯类化合物 II 的反应与 2,4,5-三氯苯氧乙酸 (Ia)、2,4,6-三甲基苯氧乙酸 (Ib) 和 4-溴-3,5-二甲基苯氧乙酸 (Ic) 在沸腾的乙醇中与 2-二乙胺基乙胺、2-吗啉基乙胺、3-吗啉基丙胺、1-甲基哌嗪、3-(4-甲基哌嗪基)丙胺、3-[4-(2-甲苯基)哌嗪]丙胺和 1,4-双(3-氨基丙基)哌嗪的反应产生了基本酰胺 Va-XIc，这些酰胺以盐酸盐的形式分离出来。酸氯化物 IVa 和 IVb 与 1,4-双(2-羟乙基)哌嗪和 1,4-双(3-羟丙基)哌嗪在二甲基甲酰胺中的反应直接产生了双酯的二盐酸盐 XIIab 和 XIIIab。制备的化合物仅具有微弱的中枢神经系统效应（主要是抑制性的）；它们具有局部麻醉、轻度降压（其中一些为肾上腺素受体拮抗剂）、抗心律失常和外周血管扩张活性。
• PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)
  申请人：FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：US20160194296A1

  公开（公告）日：2016-07-07

  The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar′, R 1 , R 2 , R 3 , R 4 , X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.

  本发明提供了化合物I或其药学上可接受的盐，其中Ar′、R1、R2、R3、R4、X、Y的定义如本发明描述中所述，作为多靶点定向配体（MTDLs），同时作为脂肪酸酰胺水解酶（FAAH）酶的抑制剂和D3多巴胺受体（D3DR）的调节剂，以及它们的制备方法、配方和治疗应用。
• 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists
  申请人：F. Hoffmann-La Roche AG

  公开号：EP0711757A1

  公开（公告）日：1996-05-15

  The present invention relates to novel α₁-adrenoceptor antagonists of Formula I: in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR⁶ (in which R⁶ is hydro or (C₁₋₆)alkyl); Y and Z are independently CH or N; R¹ is hydro, hydroxy, halo, nitro, amino, cyano, (C₁₋₄)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₄)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl(C₁₋₄)alkyl, heteroaryl(C₁₋₄)alkyl, (C₁₋₆)alkyloxy, (C₃₋₆)cycloalkyloxy, (C₃₋₆)cycloalkyl(C₁₋₄)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl(C₁₋₄)alkyloxy or heteroaryl(C₁₋₄)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R² is hydro, hydroxy, halo, cyano, (C₁₋₆)alkyl or (C₁₋₆)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R³ is -C(O)R⁷ (wherein R⁷ is (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, di(C₁₋₄)alkylamino, N-(C₁₋₄)alkyl-N-(C₁₋₄)alkyloxyamino, (C₁₋₄)alkyl((C₁₋₄)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R⁴ is halo, hydroxy, cyano, (C₁₋₆)alkyl or (C₁₋₆)alkyloxy; and R⁵ is (C₁₋₆)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.

  本发明涉及式 I 的新型 α₁-肾上腺素受体拮抗剂： 其中 p 是 0 或 1； t 是 0、1 或 2 X 是 O、S 或 NR⁶（其中 R⁶ 是氢或 (C₁₋₆)烷基）； Y 和 Z 独立地为 CH 或 N； R¹是氢、羟基、卤代、硝基、氨基、氰基、(C₁₋₄)烷硫基、乙酰氨基、三氟乙酰氨基、甲磺酰氨基、(C₁₋₆)烷基、(C₃₋₆)环烷基、(C₃₋₆)环烷基(C₁₋₄)烷基、噁唑-2-基、芳基、杂芳基、芳基(C₁₋₄)烷基、杂芳基(C₁₋₄)烷基、(C₁₋₆)烷氧基、(C₃₋₆)环烷氧基、(C₃₋₆)环烷基(C₁₋₄)烷氧基，2-丙炔氧基，芳基氧基，杂芳基氧基、芳基（C₁₋₄）烷氧基或杂芳基（C₁₋₄）烷氧基（其中烷基任选被一至三个卤原子取代，芳基或杂芳基任选被一至两个独立选自卤素和氰基的取代基取代）； R² 是氢、羟基、卤代、氰基、(C₁₋₆)烷基或(C₁₋₆)烷氧基（其中烷基任选被一至三个卤原子取代）； R³ 是 -C(O)R⁷（其中 R⁷ 是 (C₁₋₆)烷基、(C₃₋₆)环烷基、二(C₁₋₄)烷基氨基、N-(C₁₋₄)烷基-N-(C₁₋₄)烷氧基氨基、(C₁₋₄)烷基((C₁₋₄烷氧基)氨基、吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基)； R⁴ 是卤素、羟基、氰基、(C₁₋₆)烷基或 (C₁₋₆)烷氧基；和 R⁵ 是 (C₁₋₆)烷基；及其药学上可接受的盐和 N-氧化物。